Total Payments
$379,017
2022 Payments
$7,431
Companies
6
Transactions
23
Payment Breakdown by Category
Research$378,960 (100.0%)
Food & Beverage$57.23 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $378,960 | 19 | 100.0% |
| Food and Beverage | $57.23 | 4 | 0.0% |
Payments by Type
Research
$378,960
19 transactions
General
$57.23
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Banner Life Sciences, LLC | $362,642 | 13 | $0 (2021) |
| Mylan Pharmaceuticals Inc. | $8,888 | 4 | $0 (2017) |
| Eli Lilly and Company | $7,431 | 2 | $0 (2022) |
| ARBOR PHARMACEUTICALS, INC. | $27.20 | 2 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $17.60 | 1 | $0 (2018) |
| Shire North American Group Inc | $12.43 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $7,431 | 2 | Eli Lilly and Company ($7,431) |
| 2021 | $362,642 | 13 | Banner Life Sciences, LLC ($362,642) |
| 2018 | $30.23 | 2 | AstraZeneca Pharmaceuticals LP ($17.60) |
| 2017 | $8,915 | 6 | Mylan Pharmaceuticals Inc. ($8,888) |
All Payment Transactions
23 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/20/2022 | Eli Lilly and Company | — | — | In-kind items and services | $1,679.00 | Research |
| Study: A PHASE 1, RANDOMIZED, OPEN-LABEL, SINGLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN HEALTHY PARTICIPANTS | ||||||
| 03/14/2022 | Eli Lilly and Company | — | — | In-kind items and services | $5,752.00 | Research |
| Study: A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF LY3841136 IN HEALTHY AND OVERWEIGHT PARTICIPANTS | ||||||
| 10/14/2021 | Banner Life Sciences, LLC | BAFIERTAM (Drug) | — | Cash or cash equivalent | $200.00 | Research |
| Study: GI TOLERABILITY • Category: Immune | ||||||
| 08/11/2021 | Banner Life Sciences, LLC | BAFIERTAM (Drug) | — | Cash or cash equivalent | $450.00 | Research |
| Study: GI TOLERABILITY • Category: Immune | ||||||
| 07/21/2021 | Banner Life Sciences, LLC | BAFIERTAM (Drug) | — | Cash or cash equivalent | $460.25 | Research |
| Study: GI TOLERABILITY • Category: Immune | ||||||
| 06/18/2021 | Banner Life Sciences, LLC | BAFIERTAM (Drug) | — | Cash or cash equivalent | $4,931.25 | Research |
| Study: GI TOLERABILITY • Category: Immune | ||||||
| 06/08/2021 | Banner Life Sciences, LLC | BAFIERTAM (Drug) | — | Cash or cash equivalent | $1,300.00 | Research |
| Study: GI TOLERABILITY • Category: Immune | ||||||
| 05/11/2021 | Banner Life Sciences, LLC | BAFIERTAM (Drug) | — | Cash or cash equivalent | $400.00 | Research |
| Study: GI TOLERABILITY • Category: Immune | ||||||
| 04/14/2021 | Banner Life Sciences, LLC | BAFIERTAM (Drug) | — | Cash or cash equivalent | $27,056.00 | Research |
| Study: GI TOLERABILITY STUDY • Category: Immune | ||||||
| 04/06/2021 | Banner Life Sciences, LLC | BAFIERTAM (Drug) | — | Cash or cash equivalent | $1,300.00 | Research |
| Study: GI TOLERABILITY • Category: Immune | ||||||
| 03/10/2021 | Banner Life Sciences, LLC | BAFIERTAM (Drug) | — | Cash or cash equivalent | $148,574.00 | Research |
| Study: GI TOLERABILITY STUDY • Category: Immune | ||||||
| 03/10/2021 | Banner Life Sciences, LLC | BAFIERTAM (Drug) | — | Cash or cash equivalent | $700.00 | Research |
| Study: GI TOLERABILITY • Category: Immune | ||||||
| 02/04/2021 | Banner Life Sciences, LLC | BAFIERTAM (Drug) | — | Cash or cash equivalent | $176,020.00 | Research |
| Study: GI TOLERABILITY STUDY • Category: Immune | ||||||
| 02/04/2021 | Banner Life Sciences, LLC | BAFIERTAM (Drug) | — | Cash or cash equivalent | $350.00 | Research |
| Study: GI TOLERABILITY • Category: Immune | ||||||
| 01/12/2021 | Banner Life Sciences, LLC | BAFIERTAM (Drug) | — | Cash or cash equivalent | $900.00 | Research |
| Study: GI TOLERABILITY • Category: Immune | ||||||
| 09/21/2018 | AstraZeneca Pharmaceuticals LP | SYNAGIS (Biological) | Food and Beverage | In-kind items and services | $17.60 | General |
| Category: Respiratory | ||||||
| 02/20/2018 | ARBOR PHARMACEUTICALS, INC. | Otovel (Drug) | Food and Beverage | In-kind items and services | $12.63 | General |
| Category: Pediatrics/Neonatology | ||||||
| 10/09/2017 | Shire North American Group Inc | MYDAYIS (Drug) | Food and Beverage | In-kind items and services | $12.43 | General |
| Category: NEUROSCIENCE | ||||||
| 08/01/2017 | Mylan Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $675.00 | Research |
| Study: MACI-17005(2111) | ||||||
| 07/01/2017 | Mylan Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,737.50 | Research |
| Study: MACI-17005(2111) | ||||||
| 06/05/2017 | Arbor Pharmaceuticals, Inc. | Otovel (Drug) | Food and Beverage | Cash or cash equivalent | $14.57 | General |
| Category: Pediatrics/Neonatology | ||||||
| 06/01/2017 | Mylan Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $3,825.00 | Research |
| Study: MACI-17004(2110) | ||||||
| 06/01/2017 | Mylan Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $1,650.00 | Research |
| Study: MACI-17005(2111) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| GI TOLERABILITY STUDY | Banner Life Sciences, LLC | $351,650 | 3 |
| GI TOLERABILITY | Banner Life Sciences, LLC | $10,992 | 10 |
| A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF LY3841136 IN HEALTHY AND OVERWEIGHT PARTICIPANTS | Eli Lilly and Company | $5,752 | 1 |
| MACI-17005(2111) | Mylan Pharmaceuticals Inc. | $5,063 | 3 |
| MACI-17004(2110) | Mylan Pharmaceuticals Inc. | $3,825 | 1 |
| A PHASE 1, RANDOMIZED, OPEN-LABEL, SINGLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN HEALTHY PARTICIPANTS | Eli Lilly and Company | $1,679 | 1 |
About Dr. Kathleen Doisy, MD
Dr. Kathleen Doisy, MD is a Pediatrics healthcare provider based in Columbia, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1811944481.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kathleen Doisy, MD has received a total of $379,017 in payments from pharmaceutical and medical device companies, with $7,431 received in 2022. These payments were reported across 23 transactions from 6 companies. The most common payment nature is "" ($378,960).
Ad
Practice Information
- Specialty Pediatrics
- Location Columbia, MO
- Active Since 05/28/2006
- Last Updated 11/26/2007
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1811944481
Products in Payments
- BAFIERTAM (Drug) $362,642
- Otovel (Drug) $27.20
- SYNAGIS (Biological) $17.60
- MYDAYIS (Drug) $12.43
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Columbia
Dr. Stephanie Ambrose, Do, DO
Pediatrics — Payments: $29,554
Pediatrics $29,554
John Carroll, M.d, M.D
Pediatrics — Payments: $6,598
Pediatrics $6,598
Laura Alberg, M.d, M.D
Pediatrics — Payments: $6,170
Pediatrics $6,170
Richard Shrouds, Md, MD
Pediatrics — Payments: $4,808
Pediatrics $4,808
Dr. Janie Jacobs, M.d, M.D
Pediatrics — Payments: $4,793
Pediatrics $4,793
Dr. Thuy Strong, O.d, O.D
Pediatrics — Payments: $4,172
Pediatrics $4,172